New drug cocktail aims to shrink rectal tumors and avoid colostomy
NCT ID NCT07687433
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether adding two drugs—adebrelimab (an immunotherapy) and apatinib (a targeted therapy)—to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced or low-lying rectal cancer. The goal is to shrink the tumor enough to allow sphincter-preserving surgery, avoiding a permanent colostomy. The trial enrolls adults aged 18 to 75 with specific stages of rectal cancer who wish to preserve their anal sphincter.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adebrelimab and apatinib combined with chemoradiotherapy
- What this could lead to
- If successful, this approach could allow more people with low-lying rectal cancer to avoid permanent colostomy by shrinking the tumor enough to save the anal sphincter.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 43 participants. The combination may cause significant side effects, and it is not yet known if it works better than standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
No. 150, Haping Road, Nangang District, Harbin, Heilongjiang Province, China
Harbin, Heilongjiang, 158100, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test and CT combo may spare rectal cancer patients a second surgery
- Radiation may spare early rectal cancer patients from radical surgery
- Vaccinia virus targets rectal tumors in new immunotherapy combo
- New triple therapy aims to wipe out rectal cancer before surgery
- Robot vs. transanal surgery: which is better for low rectal cancer?
- New drug combo could boost rectal cancer remission before surgery